Search research articles
Contact Us
Filters
Showing results (171-180 of 180) with videos related to
Page
of 18
Sort By:
You have reached the last page of results.
This site can display upto 180 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 30, 2004
Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study
Vinay K Puduvalli, W K Alfred Yung, Kenneth R Hess, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 2006
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study
Timothy F Cloughesy, Patrick Y Wen, H Ian Robins, et al.
Journal of Neuro-Oncology
|
October 13, 2006
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme
Morris D Groves, Vinay K Puduvalli, Susan M Chang, et al.
Neuro-Oncology
|
January 29, 2014
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02
Patrick Y Wen, Susan M Chang, Kathleen R Lamborn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 28, 2022
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
Andrew B Lassman, Juan Manuel Sepúlveda-Sánchez, Timothy F Cloughesy, et al.
Neuro-Oncology Advances
|
April 24, 2026
Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial
Byram H Ozer, Adam L Cohen, Howard Colman, et al.
Neuro-Oncology
|
September 21, 2014
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma
Marta Penas-Prado, Kenneth R Hess, Michael J Fisch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 18, 2006
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, et al.
Nature Medicine
|
July 21, 2025
Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Farshad Nassiri, Vikas Patil, Leeor S Yefet, et al.
Nature Medicine
|
May 15, 2023
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Farshad Nassiri, Vikas Patil, Leeor S Yefet, et al.
Page
of 18
Search research articles
Search
Showing results (171-180 of 180) with videos related to
Sort By:
Page
of 18
You have reached the last page of results.
This site can display upto 180 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 30, 2004
Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study
Vinay K Puduvalli, W K Alfred Yung, Kenneth R Hess, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 2006
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study
Timothy F Cloughesy, Patrick Y Wen, H Ian Robins, et al.
Journal of Neuro-Oncology
|
October 13, 2006
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme
Morris D Groves, Vinay K Puduvalli, Susan M Chang, et al.
Neuro-Oncology
|
January 29, 2014
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02
Patrick Y Wen, Susan M Chang, Kathleen R Lamborn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 28, 2022
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
Andrew B Lassman, Juan Manuel Sepúlveda-Sánchez, Timothy F Cloughesy, et al.
Neuro-Oncology Advances
|
April 24, 2026
Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial
Byram H Ozer, Adam L Cohen, Howard Colman, et al.
Neuro-Oncology
|
September 21, 2014
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma
Marta Penas-Prado, Kenneth R Hess, Michael J Fisch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 18, 2006
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, et al.
Nature Medicine
|
July 21, 2025
Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Farshad Nassiri, Vikas Patil, Leeor S Yefet, et al.
Nature Medicine
|
May 15, 2023
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Farshad Nassiri, Vikas Patil, Leeor S Yefet, et al.
Page
of 18